Department of Dermatology, Austin Repatriation Medical Centre, Melbourne, Victoria, Australia.
Australas J Dermatol. 2012 Feb;53(1):57-60. doi: 10.1111/j.1440-0960.2011.00853.x. Epub 2012 Jan 6.
We report the cases of two patients who developed eruptive cutaneous squamous cell carcinomas (SCC) soon after commencement of ustekinumab, as treatment of moderate to severe plaque type psoriasis. Ustekinumab is a human monoclonal antibody with a novel mechanism, selectively targeting the shared p40 subunit of interleukin-12 (IL-12) and IL-23. Its efficacy has been well documented in three large phase-III trials (PHOENIX I, PHEONIX 2, ACCEPT). Safety data on this new biological agent continue to grow. To date, no link between ustekinumab and cutaneous carcinogenesis has been demonstrated and, to our knowledge, these cases are the first of their kind. Importantly, both these patients had independent risk factors for developing non-melanoma skin cancers; however, the specific time correlation with the administration of ustekinumab is of note. Our report suggests that ustekinumab may allow the development of cutaneous carcinomata in predisposed individuals.
我们报告了两例患者的病例，他们在开始使用乌司奴单抗（ustekinumab）治疗中度至重度斑块型银屑病后不久，就出现了突发性皮肤鳞状细胞癌（SCC）。乌司奴单抗是一种新型的人源单克隆抗体，其作用机制独特，可选择性靶向白细胞介素-12（IL-12）和 IL-23 的共同 p40 亚单位。三项大型 III 期临床试验（PHOENIX I、PHEONIX 2 和 ACCEPT）已经充分证明了其疗效。关于这种新型生物制剂的安全性数据不断增加。迄今为止，尚未证明乌司奴单抗与皮肤癌变之间存在关联，据我们所知，这些病例属于首例。重要的是，这两个患者都有发生非黑色素瘤皮肤癌的独立风险因素；然而，与乌司奴单抗给药的具体时间相关性值得注意。我们的报告表明，乌司奴单抗可能使易患个体发生皮肤癌。
